-+ 0.00%
-+ 0.00%
-+ 0.00%

U.S. FDA APPROVES RYBREVANT FASPRO™ (AMIVANTAMAB AND HYALURONIDASE-LPUJ) CO-FORMULATED WITH ENHANZE® FOR THE TREATMENT OF ADVANCED EGFR-MUTATED NON-SMALL CELL LUNG CANCER

Reuters·12/18/2025 12:00:05

Please log in to view news